March 14, 2017

Fluciclovine PET/CT improves radiotherapy targeting for recurrent prostate cancer

The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.  {read more here}